Overview
Sunshine Holdings is a diversified group spanning healthcare, consumer products and agribusiness. Healthcare is the largest business, supported by pharmaceutical distribution, medical devices and manufacturing, while consumer brands and plantations broaden the earnings base.
The key change is a widening gap between top-line growth and profitability. The latest quarter brought strong revenue expansion, but operating and net profit declined, leaving margin recovery and cost control as the central issues.
Price performance
SUN fell 15.8% over six months, versus a 9.8% decline for the ASPI. Over one year it gained 5.3%, still behind the index's 9.0% rise. The closing price was LKR 29.90 as at 12 August 2026, the reference price for the multiples in this report.
The share sat at 23.6% of its 52-week range, closer to the low than the high. Recent volatility was 25.8% below its own one-year level, while 20-day volume was 44.7% below its 60-day average, indicating quieter trading rather than a broad increase in activity.
Valuation
SUN trades on 19.28 times earnings and 3.03 times book value, against diversified-holding sector medians of 11.48 and 1.18. These place the P/E at the 88th sector percentile and P/B at the 95th, so the stock is priced near the expensive end of its peer set despite recent earnings pressure.
Return on equity was 15.3% for the audited year ended March 2026, while the dividend yield was 6.0%, at the 93rd sector percentile. The payout has risen from LKR 0.75 per share in FY2024 to LKR 0.975 in FY2025 and LKR 1.80 in FY2026, but the latest payout ratio of 116.0% and dividend cover of 0.86 times show that the distribution exceeded reported earnings.
News and sentiment
Coverage was broadly positive: 15 material articles in the 90-day window comprised 8 positive, 1 negative and 6 neutral reports. The latest 30-day flow included 2 articles against a monthly baseline of 3.0, which is about normal rather than unusually loud.
Company news highlighted the Zydus partnership to develop local pharmaceutical manufacturing and the acquisition of a majority stake in Joint Agri Products Ceylon. Confirmed dividend ex-dates were 17 November 2025, 19 February 2026 and 26 June 2026. A 1:4 share subdivision had an ex-date of 19 February 2025, so per-share comparisons before and after that date require the restated share basis.
Financials
In the quarter ended 30 June 2026, revenue rose 16.6% year-on-year to LKR 18.54 billion, but operating profit fell 7.7% to LKR 2.44 billion and net profit fell 15.2% to LKR 1.41 billion. This is the clearest current tension: sales grew, but earnings weakened.
Gross margin fell from 31.8% to 28.1%, operating margin from 16.6% to 13.2% and net margin from 10.4% to 7.6%. Each was the worst of seven comparable June quarters in the company's history. The LKR 1.03 billion gap between operating profit and net profit remained a substantial below-the-line drag.
The latest media reports, dated 10 and 11 August 2026, described the same quarter as revenue of LKR 18.5 billion and PAT of LKR 1.4 billion, with PAT reported as up 6.0% and EBIT down 7.8%. Those reported figures differ from the filed dataset's net-profit comparison, so the two should not be merged. The company has a structural seasonal pattern in operating margin, with March weakest and September strongest, but June 2026 was not the seasonal extreme.
Risks
The largest financial risk is that profit is not translating into cash. For the year ended March 2026, gearing was 47.8% of owners' equity, interest cover was 12.94 times and the current ratio was 1.73, so leverage and liquidity were manageable at that date, but twelve-month cash conversion was negative 0.16 times.
Total debt was LKR 9.5 billion against cash of LKR 7.4 billion at March 2026. Minority shareholders received 39.4% of group profit, meaning consolidated net profit and the earnings attributable to SUN shareholders are materially different pots of money. Healthcare pricing pressure is especially important because healthcare represents 57% of reported segment revenue, while consumer costs and agribusiness labour constraints add smaller but separate exposures.
Outlook
As at 12 August 2026, the next identifiable company event is the filing for the quarter ending 30 September 2026, expected from 31 October 2026 to 26 January 2027. It will supersede the June figures and show whether the media-reported PAT improvement is reflected consistently in the next filing; the present data cannot reconcile that discrepancy.
The healthcare sector, representing 57% of reported segment revenue, is receiving support from industry calls for pharmaceutical manufacturing and exports, which is relevant to Sunshine's Zydus project but does not yet establish an earnings outcome. Easing domestic market rates could reduce financing pressure across the economy, while 7.3% inflation and a roughly 47% fuel-price increase remain cost risks. The next filing is therefore the key test of whether revenue growth is reaching operating profit.